{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:09:10Z","timestamp":1782248950360,"version":"3.54.5"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>This double-blind placebo-controlled, fixed\/flexible-dose phase 2 trial assessed the efficacy, safety, and tolerability of cariprazine vs. placebo for depressive episodes associated with bipolar I or II disorder. Primary endpoint was change in Montgomery\u2013\u00c5sberg Depression Rating Scale (MADRS) total scores (baseline to week 8), and secondary endpoint was mean Clinical Global Impressions-Improvement score (week 8). Patients were randomized (<jats:italic toggle=\"yes\">N<\/jats:italic>\u2009=\u2009233) 1:1:1 to placebo, \u2018low-dose\u2019 0.25\u20130.5\u2009mg\/day or \u2018high-dose\u2019 1.5\u20133.0\u2009mg\/day cariprazine. Adverse events, laboratory results, vital signs, extrapyramidal symptoms, and suicide risk were monitored. Neither cariprazine group significantly separated from placebo in primary (mixed-effect model repeated measures MADRS least-squares mean differences: low-dose\u2009=\u2009\u22120.7, <jats:italic toggle=\"yes\">P\u2009<\/jats:italic>=\u20090.7408; high-dose\u2009=\u20090.0, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.9961) or secondary efficacy measures. No new safety signals with cariprazine were observed and common treatment-emergent adverse events (\u22655% of cariprazine patients and twice the rate of placebo) included insomnia, akathisia, dry mouth, nausea, weight increased, diarrhea, restlessness, vomiting, musculoskeletal stiffness, migraine, and cough. Metabolic and weight changes were generally similar for cariprazine and placebo. Factors that may have affected the outcome of the trial were identified, which helped to inform the design and conduct of subsequent phase 2b\/3 clinical trials of cariprazine in bipolar depression.<\/jats:p>","DOI":"10.1097\/yic.0000000000000307","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T13:02:36Z","timestamp":1581685356000},"page":"147-156","source":"Crossref","is-referenced-by-count":34,"title":["Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial"],"prefix":"10.1097","volume":"35","author":[{"given":"Lakshmi N.","family":"Yatham","sequence":"first","affiliation":[{"name":"University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[{"name":"Bipolar and Depressive Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie","family":"Earley","sequence":"additional","affiliation":[{"name":"Allergan Plc, Madison, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230926","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision).","volume":"159","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R3-20230926","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/10673221003747955","article-title":"Bipolar depression: overview and commentary.","volume":"18","author":"Baldessarini","year":"2010","journal-title":"Harv Rev Psychiatry"},{"key":"R4-20230926","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R5-20230926","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jad.2007.06.011","article-title":"The empirical redefinition of the psychometric criteria for remission in bipolar disorder.","volume":"106","author":"Berk","year":"2008","journal-title":"J Affect Disord"},{"key":"R6-20230926","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0893-133X(96)00242-4","article-title":"Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response.","volume":"16","author":"Blier","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"R7-20230926","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s004060070016","article-title":"Suicidality in bipolar compared to unipolar depressed inpatients.","volume":"250","author":"Bottlender","year":"2000","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R8-20230926","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","article-title":"A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.","volume":"162","author":"Calabrese","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R9-20230926","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/0006-3223(95)00295-2","article-title":"Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorder relative to subjects with other axis I disorders.","volume":"39","author":"Chen","year":"1996","journal-title":"Biol Psychiatry"},{"key":"R10-20230926","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1399-5618.2008.00625.x","article-title":"Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics.","volume":"10","author":"Correll","year":"2008","journal-title":"Bipolar Disord"},{"key":"R11-20230926","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881111408461","article-title":"Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis.","volume":"26","author":"De Fruyt","year":"2012","journal-title":"J Psychopharmacol"},{"key":"R12-20230926","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-Week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression.","volume":"173","author":"Durgam","year":"2016","journal-title":"Am J Psychiatry"},{"key":"R13-20230926","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1176\/appi.ajp.2018.18070824","article-title":"Cariprazine treatment of bipolar depression: a randomized, double blind, placebo-controlled phase 3 study.","volume":"176","author":"Earley","year":"2019a","journal-title":"Am J Psychiatry"},{"key":"R14-20230926","article-title":"Efficacy and safety of cariprazine in bipolar I depression: a double blind, placebo-controlled phase 3 study.","author":"Earley","year":"2019b","journal-title":"Bipolar Disord"},{"key":"R15-20230926","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/archgenpsychiatry.2009.43","article-title":"The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11C]-(+)-PHNO.","volume":"66","author":"Graff-Guerrero","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"R16-20230926","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-642-25758-2_7","article-title":"The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions.","volume":"213","author":"Gross","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"R18-20230926","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R19-20230926","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.4088\/JCP.11r07485","article-title":"Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.","volume":"73","author":"Iovieno","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"R20-20230926","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0165-0327(14)70007-2","article-title":"Managing the side effects associated with commonly used treatments for bipolar depression.","volume":"169","author":"Kemp","year":"2014","journal-title":"J Affect Disord"},{"key":"R21-20230926","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.NMD.0000061144.16176.38","article-title":"Placebo response and antidepressant clinical trial outcome.","volume":"191","author":"Khan","year":"2003","journal-title":"J Nerv Ment Dis"},{"key":"R22-20230926","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1176\/appi.ajp.161.11.2045","article-title":"Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.","volume":"161","author":"Khan","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R23-20230926","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.","volume":"333","author":"Kiss","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R24-20230926","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1399-5618.2007.00467.x","article-title":"Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder.","volume":"9","author":"Kupka","year":"2007","journal-title":"Bipolar Disord"},{"key":"R26-20230926","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"R27-20230926","doi-asserted-by":"crossref","first-page":"S550","DOI":"10.1016\/S0924-977X(16)31595-4","article-title":"Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, marder factors, and cognition.","volume":"26","author":"Marder","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"R28-20230926","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S2215-0366(16)30264-4","article-title":"Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials.","volume":"3","author":"McGirr","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"R29-20230926","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2011.05.005","article-title":"Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO.","volume":"131","author":"Mizrahi","year":"2011","journal-title":"Schizophr Res"},{"key":"R30-20230926","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"R31-20230926","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.euroneuro.2013.05.006","article-title":"The potential role of dopamine D(3) receptor neurotransmission in cognition.","volume":"23","author":"Nakajima","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"R32-20230926","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1176\/appi.ajp.2013.13020185","article-title":"The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.","volume":"170","author":"Pacchiarotti","year":"2013","journal-title":"Am J Psychiatry"},{"key":"R33-20230926","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/FBP.0000000000000070","article-title":"Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression.","volume":"25","author":"Papp","year":"2014","journal-title":"Behav Pharmacol"},{"key":"R34-20230926","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia\u2013Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"R35-20230926","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/NMD.0b013e31827189d4","article-title":"The sorry state of treatment research in bipolar disorder: an ongoing but preventable catastrophe.","volume":"200","author":"Post","year":"2012","journal-title":"J Nerv Ment Dis"},{"key":"R36-20230926","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.psc.2015.09.001","article-title":"Treatment of bipolar depression: evolving recommendations.","volume":"39","author":"Post","year":"2016","journal-title":"Psychiatr Clin North Am"},{"key":"R37-20230926","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/14656566.2019.1660319","article-title":"Efficacy and safety of cariprazine in the treatment of bipolar disorder.","volume":"20","author":"Saraf","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"R39-20230926","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand suppl"},{"key":"R40-20230926","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1192\/bjp.148.5.599","article-title":"Grade scores of the montgomery-asberg depression and the clinical anxiety scales.","volume":"148","author":"Snaith","year":"1986","journal-title":"Br J Psychiatry"},{"key":"R42-20230926","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/jcp.0b013e3181618eb4","article-title":"Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.","volume":"28","author":"Thase","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R43-20230926","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","article-title":"Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).","volume":"26","author":"Thase","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R44-20230926","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1192\/bjp.bp.112.108357","article-title":"Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.","volume":"201","author":"Tohen","year":"2012","journal-title":"Br J Psychiatry"},{"key":"R45-20230926","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-5618.2006.00341.x","article-title":"Prospective study of risk factors for attempted suicide among patients with bipolar disorder.","volume":"8","author":"Valtonen","year":"2006","journal-title":"Bipolar Disord"},{"key":"R47-20230926","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"R48-20230926","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1192\/bjp.bp.114.147587","article-title":"Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial.","volume":"208","author":"Yatham","year":"2016","journal-title":"Br J Psychiatry"},{"key":"R49-20230926","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity, and sensitivity.","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"}],"container-title":["International Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/YIC.0000000000000307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T17:14:41Z","timestamp":1695748481000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/YIC.0000000000000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/yic.0000000000000307","relation":{},"ISSN":["0268-1315"],"issn-type":[{"value":"0268-1315","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}